LyngLab

The Lyng Lab works to develop biomarkers and drug targets in radiotherapy of cancer. We are located at Institute for Cancer Research, Oslo University Hospital.

[LyngLab @LyngLab]

Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter ##mdpicancers via @Cancers_MDPI

[LyngLab @LyngLab]

Congratulations! Looking forward to follow this exciting work!

[Brita Singers Sørensen @BritaSingers]

First biological experiment at DCPT! There will be many more to come!
#Radiobiology #DCPT #protontherapy #dcccradiotherapy

[LyngLab @LyngLab]

Look to Denmark @Kreftforeningen

[Magnus Heunicke @Heunicke]

Min første handling som sundhedsminister: Jeg udsteder en bekendtgørelse, der giver gratis HPV-vaccine til drenge 💉👍
Tak for forarbejdet til mine forgængere i den tidligere regering. Nu går vi i gang.
#vaccinervirker #sundpol #dkpol

[LyngLab @LyngLab]

@chrisfje

[Francesca Buffa @BuffaFrancesca]

Glad to see this published. Please feel free to check out our sigQC protocol and R package!
@andrewdhawan @barberis_ale @CatharineWest3 @CancerConnector @tim_maughan @The_OIRO @CRUKOxford #mathonco @NatureProtocols https://t.co/kA7rRgKdmh

[LyngLab @LyngLab]

@chrisfje

[Tracy Underwood @TsaUnderwood]

Beautiful correlation between image (ABrix) and gene-based biomarkers for hypoxia / poor prognosis in cervical cancer from Christina Saeten Fjeldbo and Heidi Lyng in Oslo #BIGART2019

[Tracy Underwood @TsaUnderwood]

Prof Gillies McKenna highlights several exciting prospects for particle therapy: differences in immune response, radio sensitisers, FLASH & microbeam (more understanding needed) & solving bottlenecks in treatment planning via artificial intelligence and machine learning #PTCOG58